- Home
- QUCY vs BYSI Comparison
QUCY vs BYSI Comparison
Compare QUCY & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | QUCY | BYSI |
|---|---|---|
| Founded | 2008 | 2010 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.5M | 35.8M |
| IPO Year | 2021 | 2016 |
Fundamental Metrics
Financial Performance| Metric | QUCY | BYSI |
|---|---|---|
| Price | $1.48 | $0.84 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 644.5K | ★ 1.9M |
| Earning Date | 06-26-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 87.68 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $537,080.00 | N/A |
| Revenue This Year | $74.34 | N/A |
| Revenue Next Year | $171.48 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.30 | $0.73 |
| 52 Week High | $4.93 | $2.44 |
Technical Indicators
Market Signals| Indicator | QUCY | BYSI |
|---|---|---|
| Relative Strength Index (RSI) | 54.13 | 35.32 |
| Support Level | $1.38 | N/A |
| Resistance Level | $1.55 | $1.84 |
| Average True Range (ATR) | 0.13 | 0.11 |
| MACD | 0.04 | -0.00 |
| Stochastic Oscillator | 72.24 | 18.92 |
Price Performance
Historical ComparisonAbout QUCY Mainz Biomed N.V. Ordinary Shares
Quantum Cyber NV is focused on building a diversified platform at the intersection of quantum computing and cybersecurity. It aims to secure critical infrastructure and data against these emerging threats.
About BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.